Skip to main content Skip to footer
Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc.
  • Home
  • About Us
    • Our Story
    • Our Mission, Vision, Values
    • Our Team
    • Our Partners
    • Investors & Media
  • Patients
    • About Lupus Nephritis
    • Resources
    • Patient Support Program
    • Aurinia in Action
  • Our Science
    • Our Product
    • Our Pipeline
    • Our Research and Data
  • Investors & Media
    • News & Events
    • Corporate Presentation
    • Financial Info
    • Stock Data
    • SEC Filings
    • ESG
    • Board of Directors
    • Governance
    • Investor Tools
  • Aurinia Gives
    • Aurinia Gives
    • CME Grants
    • Charitable Giving FAQs
    • Sponsorships
    • Charitable Donations
    • Patient-Centered Care Grants
  • Careers
    • Our Culture
    • Our Benefits
    • Notice to Recruiters
    • Careers Contact
    • Open Positions
  • Contact Us
    • Report an Adverse Event

Press Releases

Investors & Media

Investors & Media

  • News & Events
    • Press Releases
    • IR Calendar
    • 2025 AGM
  • Corporate Presentation
    • Corporate Presentation
  • Financial Info
    • Financial Results
  • Stock Data
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Filings
  • ESG
  • Board of Directors
  • Governance
  • Investor Tools
    • Overview
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News & Events

  • Press Releases
  • IR Calendar
  • 2025 AGM
September 2, 2015 • 9:00 am EDT

Aurinia Pharmaceuticals to Present at the 2015 Rodman & Renshaw 17th Annual Global Investment Conference

August 11, 2015 • 5:15 pm EDT

Aurinia Reports Second Quarter 2015 Financial Results

August 6, 2015 • 9:00 am EDT

Aurinia Pharmaceuticals to Present at the Canaccord Genuity 35th Annual Growth Conference

May 27, 2015 • 5:58 pm EDT

Aurinia Announces Results of Annual General Meeting

May 19, 2015 • 2:14 pm EDT

Aurinia Pharmaceuticals to Present at the 2015 UBS Global Health Care Conference

May 15, 2015 • 5:00 pm EDT

Aurinia Reports First Quarter 2015 Financial Results and Restatement of 2014 Financial Statements

April 23, 2015 • 5:07 pm EDT

Aurinia Pharmaceuticals to Host Lupus Nephritis Opinion Leader Meeting and Webcast on May 5 in New York

March 30, 2015 • 5:24 pm EDT

Aurinia Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Initiation of Its Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers

March 6, 2015 • 7:00 pm EST

Aurinia Announces Change to Its Board of Directors

February 26, 2015 • 6:08 pm EST

Aurinia Pharmaceuticals to Present at Cowen and Company 35th Annual Health Care Conference

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 26
  • Page 27
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • Page 34
  • Page 35
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed

<h2>We are passionate about changing the trajectory of autoimmune diseases.<br>Join us.</h2>

Business Development

bd@auriniapharma.com

Investor Relations

ir@auriniapharma.com

Clinical Trials

clinicaltrials@auriniapharma.com

Medical Information

medinfo@auriniapharma.com

Corporate Communications and Media Inquiries

AChristopher@auriniapharma.com

Patient Safety

Report an Adverse Event
Privacy Statement Terms of Use Disclaimer Aurinia Community Guidelines Aurinia Compliance Program Manage Cookie Preferences
©2025 Aurinia Pharmaceuticals Inc. All Rights Reserved. US-LUP-2300105 08/23
Back to top

Navigating away from Aurinia

You are about to leave the Aurinia Pharmaceuticals website. We are not responsible for the content or accuracy of information on any third-party websites nor do we monitor or endorse such websites. If you would like to leave the Aurinia website and visit the third-party website, please select CONTINUE.